Algorae Pharmaceuticals Limited · ASX:1AI
Algorae Pharmaceuticals — Non-Deal Roadshow (April 2024)
25 slides from Algorae Pharmaceuticals's roadshow presentation, Apr 18, 2024
Slide 1: Non-deal Corporate Presentation
For personal use only Non-deal Corporate Presentation ASX Code: 1AI April 2024
Slide 2: Disclaimer: Important Information
Disclaimer: Important Infor mation For personal use only Not an offer of Securities. This document has been independently prepared by Algorae Pharmaceuticals Ltd (Algorae) and is provided for informational purposes only. This document does not constitute or contain an offer, invitation, solicitation
Slide 3: Corporate Overview
Corporate Overview For personal use only $0.01 $3.6 million 1AI share price* Cash (31 Dec 23) 1.68 billion 306 million Shares on issue ITM Listed options** 45% $16.8 million Top 20 Market capitalisation * Price as at 17 April 2024 ** ITM Listed options: 1AIO ($0.012, exp 31/03/26), OTM listed option
Slide 4: Mission In Action
Mission In Action • AlgoraeOS artificial intelligence platform to expand For personal use only therapeutic pipeline of assets • First AlgoraeOS readout of fixed dose combination Algorae is a biopharmaceutical company drug targets expected Q2/Q3 2024 aiming to transform the cost, pace, and • 2 combin
Slide 5: Artificial intelligence promises to revolutionise drug discovery
A r t i f i c i a l i n t e l l i g e n c e p ro m i s e s Transforming Drug Discovery For personal use only to revolutionise drug discovery with AI-enabled technology Only 6% of clinical trials using Drug development is accelerated by using traditional drug discovery data driven and AI-enabled appr
Slide 6: Artificial Intelligence for Combination Drug Discovery
Artificial Intelligence for Combination Drug Discovery For personal use only AlgoraeOS utilises machine learning, deep learning and neural network artificial intelligence within extensive existing databases to predict synergistic pharmaceutical fixed-dose combination (FDC) drug targets, aimed at imp
Slide 7: AlgoraeOS Development & Infrastructure
A l g o r a e O S D e v e l o p m e n t & I n f r a s t r u c t u re For personal use only Collaborating with UNSW Data Science Hub and CSIRO Data61 to harness cutting-edge data science and technology, AlgoraeOS is being developed by the leading artificial intelligence experts and institutions in Au
Slide 8: AlgoraeOS AI-enabled Drug Discovery Platform
AlgoraeOS AI-enabled Drug Discovery Platform Spend less for discovery and move faster to development For personal use only Data Analysis & Integration Target Identification & Validation Analysing vast amounts of biological, chemical, and clinical Predict and prioritise potential drug targets by anal
Slide 9: AlgoraeOS Synergistic Drug Combination Prediction
AlgoraeOS Synergistic Drug Combination Prediction • Extensive scientific and medical databases compiled and For personal use only customised for data processing and standardisation • AI model utilises machine learning, deep learning and neural networks • Screening for fixed dose combination drug tar
Slide 10: AlgoraeOS Pillars of Data for Drug Discovery
AlgoraeOS 4 Pillars of Data For personal use only for Drug Discovery Corporate Presentation | April 2024 (ASX: 1AI) 10
Slide 11: AlgoraeOS Business Model
AlgoraeOS Business Model For personal use only 3 key opportunities to create shareholder value using our artificial intelligence platform Corporate Presentation | April 2024 (ASX: 1AI) 11
Slide 12: BioPharma with AI-enabled Business Models
BioPharma with USD AUD AI-enabled For personal use only 1AI Algorae Pharmaceuticals Ltd $10.8M $16.9M* Business RXRX Recursion Pharmaceuticals Inc $1.78B $2.78B Models RLAY Relay Therapeutics Inc $884M $1.38B Algorae is the only AI-enabled biopharma EXAI Excientia Plc $537M $839M company focused on
Slide 13: Combination Drugs: New & Improved Pharmaceuticals
C o m b i n a t i o n D r u g s : N e w & I m p ro v e d P h a r m a c e u t i c a l s Fixed-dose combination drugs (FDCs) are medicines comprising 2 or more active pharmaceutical ingredients combined For personal use only in a single dose. Algorae leverage existing data generated on individual drug
Slide 14: AlgoraeOS: Differentiated from International Peers
AlgoraeOS: Differentiated from Inter national Peers Specialisation One: Fixed Dose Combination Pharmaceuticals For personal use only Specialisation Two: Cannabinoids • Cannabinoid compounds, as well as fixed dose combination drug predictions sets AlgoraeOS apart from international peer platforms • W
Slide 15: AI-116 Dementia
For personal use only AI-116 Dementia
Slide 16: Dementia Drug Market
Dementia Est. Market Size (2024) USD$21 billion 3 Drug Market For personal use only Est. Market Size (2033) USD$170 billion Market data pertains to acetylcholinesterase Inhibitors, CAGR (2024-2033) 8.20% known as Donepezil, Rivastigmine and Galantamine. Dementia and neurocognitive diseases, such as
Slide 17: Cannabinoids to Improve Existing Dementia Treatments
Cannabinoids to Improve For personal use only E x i s t i n g D e m e n t i a Tr e a t m e n t s AI-116 combines an acetylcholinesterase inhibitor and cannabidiol in a novel fixed dose combination designed to enhance an existing treatment. Neurocognitive diseases, like Alzheimer’s, share many of the
Slide 18: AI-116 Dementia: Preliminary Results
AI-116 Dementia: Preliminary Results For personal use only • Preliminary in vitro data demonstrates the neuroprotective effect of AI-116, exceeding that of the existing FDA registered acetylcholinesterase inhibitor. • Cell viability increased by 20.1% for AI-116 versus 2.1% for and existing acetylch
Slide 19: AI-168 Cardiovascular Disease
For personal use only AI-168 Cardiovascular Disease
Slide 20: Cardiovascular Drug Market
Cardiovascular Est. Market Size (2023) USDS$66.7 billion 5 Drug Market For personal use only Est. Market Size (2032) USD$84.5 billion CAGR (2023-2029) 2.7% Cardiovascular disease (CVD) is the leading cause of death worldwide with an estimated 18 millions deaths attributable in 2019 alone In 2017 in
Slide 21: Cannabinoids to Improve Treatments for Cardiovascular Disease
C a n n a b i n o i d s t o I m p r o v e Tr e a t m e n t s f o r C a r d i o v a s c u l a r D i s e a s e For personal use only AI-168 comprises a cannabinoid and another drug in combination. Cannabinoids have been reported to be therapeutically beneficial in models of myocardial infarction, arrh
Slide 22: Board of Directors
Board of Directors For personal use only • Significant shareholders in the business Mr. David Hainsworth Executive Chairman • Extensive experience building and funding high growth companies on ASX Mr. Brad Dilkes • Established record of collaborating with Non-executive Director expert scientists, in
Slide 23: Scientific Leadership Team
Scientific Leadership Team For personal use only Dr. James McKenna (Algorae) Prof. Garrie Arumugam (LTU) Chief Scientific Officer Dementia A/Prof. Fatemeh Vafaee (UNSW) Dr. Muhammad Heydari (UNSW) Artificial Intelligence Artificial Intelligence Dr. Kristen Bubb (Monash) Dr. Giannie Barsha (Monash) C
Slide 24: Upcoming Catalysts
Upcoming Catalysts For personal use only • Launch of AI platform, AlgoraeOS • Artificial intelligence scans for drug targets • Additional pre-clinical results from AI-116 for Dementia • Pre-clinical results from AI-168 for Cardiovascular Disease • Data acquisitions for AI platform • Data sharing and
Slide 25: Appendix: References / Cited Sources
Appendix References / Cited Sources For personal use only Slide 5: FDA Approvals 1.Link to cited information Website: https://algoraepharma.com Slide 14: GW Pharmaceuticals Takeover 2. Link to cited information Media Inquiries: brad@algoraepharma.com Slide 16: Dementia Drug Market Level 23, Rialto S
Algorae Pharmaceuticals — Non-Deal Roadshow (April 2024) on 6ix